Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.

Journal Article (Journal Article)

CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.

Full Text

Duke Authors

Cited Authors

  • Johnson, LA; Sanchez-Perez, L; Suryadevara, CM; Sampson, JH

Published Date

  • 2014

Published In

Volume / Issue

  • 3 / 7

Start / End Page

  • e944059 -

PubMed ID

  • 25610729

Pubmed Central ID

  • PMC4292711

International Standard Serial Number (ISSN)

  • 2162-4011

Digital Object Identifier (DOI)

  • 10.4161/21624011.2014.944059


  • eng

Conference Location

  • United States